MEDIA

EVENTS

We are delighted to announce that Fondazione Gianni Benzi will participate in the World Orphan Drug Congress 2024, which will be held in Barcelona from October 22-25.
Our Head of Research and Innovation Department, Viviana Giannuzzi, will give a talk on "Ethics and regulatory guidance for not-for-profit research for rare diseases: the experience of a European funded programme" and join a panel discussion on How does Access to healthcare, treatment and diagnosis differ across Europe.
The World Orphan Drug Congress is the leading international conference for the orphan drug industry. It brings together experts from around the world to discuss the latest developments in orphan drug research, development and commercialisation.
The conference will cover a wide range of topics, including:
• Research and development of orphan drugs
• Commercialisation of orphan drugs
• Orphan drug policy
• Patient advocacy
• Global health
The conference will feature presentations by leading experts in the field of orphan drugs. There will also be opportunities for networking and poster presentations.
We are proud to be part of this important event and to have the opportunity to share our expertise with the global community. We believe that our work in rare disease research is making a real difference in the lives of patients and their families.
We invite you to visit the World Orphan Drug Congress website for more information.

 

Subscribe To Our Newsletter

to keep you up to date on our activities and initiatives

La tua iscrizione non può essere convalidata.
La tua iscrizione è avvenuta correttamente.

We use Brevo as our marketing platform. By clicking below to submit this form, you are aware and accept that the information you have provided will be transferred to Brevo for treatment in accordance with their terms of use
Utilizziamo Brevo come nostra piattaforma di marketing. Cliccando qui sotto per inviare questo modulo, sei consapevole e accetti che le informazioni che hai fornito verranno trasferite a Brevo per il trattamento conformemente alle loro condizioni d'uso

You have Successfully Subscribed!